searl News

News Image

Searle profit rises 31% to Rs1bn in 1QFY27

Consolidated profit for the period of The Searle Company Limited (PSX: SEARL) rose 30.77% year-on-year to Rs1.20bn for the three months ended September 30, 2026, compared with Rs914.15m in the same period last year.

 Go to article
News Image

VIS reaffirms The Searle Company's long-term rating at 'AA-'

The Searle Company Limited (PSX:SEARL) has had its entity ratings reaffirmed by VIS Credit Rating Company Limited (VIS) at 'AA-/A1' (Double A Minus/A One), with a 'Stable' outlook.

 Go to article
News Image

Searle swings to Rs536m profit, declares Rs1/share dividend

The Searle Company Limited (PSX: SEARL) swung to a consolidated net profit of Rs535.74m for the year ended June 30, 2026, reversing a loss of Rs1.37bn (restated) recorded in the corresponding period last year a complete earnings turnaround driven by the elimination of a substantial discontinued operations loss and strong core business growth.

 Go to article
News Image

Searle to transfer biologic portfolio to Nextar

The Searle Company Limited's (PSX: SEARL) board has approved the transfer of its biological and associated products portfolio to its indirect subsidiary, Nextar Pharma (Private) Limited, in a transaction valued at up to Rs4 billion, subject to shareholder approval.

 Go to article
News Image

Searle strikes a high note

The Searle Company Limited (PSX:SEARL) reported an explosive surge in net profit to Rs1.81bn for the half year ended December 31, 2025, a staggering 26.05 times higher than the Rs69.35m profit recorded in the same period last year.

 Go to article
News Image

Searle launches Ostegem OD & M-Folate OD in Canada

In a significant stride toward global expansion, The Searle Company Limited, one of Pakistan’s leading pharmaceutical manufacturers, has launched Ostegem OD and M-Folate OD in Canada, with availability confirmed across multiple pharmacies in the Greater Toronto Area (GTA).

 Go to article
News Image

Searle achieves DRAP registration for Denosumab biosimilars

The Searle Company Limited (PSX: SEARL) has successfully obtained registration of Denosumab injections 120mg and 60mg (biosimilar drugs) from the Drug Regulatory Authority of Pakistan.

 Go to article
News Image

SEARL secures GCC approval for manufacturing facility in Qatar

The Searle Company Limited (PSX: SEARL) achieved a significant milestone with the approval of its manufacturing facility by the Ministry of Public Health...

 Go to article
News Image

Searle reports 11.8% drop in revenue, profit down 7.4% in Q3

The Searle Company Limited (PSX: SEARL) experienced a fall of 7.4% YoY in its quarterly earnings, with its profit after tax falling to Rs300.78 million...

 Go to article
News Image

SEARL suffers loss of Rs3.3bn in FY24 due to impairment loss

The Searle Company Limited (PSX: SEARL) suffered a loss of Rs3.33 billion [LPS: Rs6.95] for the year ended June 30, 2024, due to a substantial loss...

 Go to article
Name Price/Vol %Chg/NChg
KSE100 168,018.87
212.27M 		0.87%
1454.80
ALLSHR 101,001.36
515.85M 		0.66%
661.96
KSE30 49,411.77
62.47M 		0.83%
408.34
KMI30 240,580.99
77.70M 		0.99%
2354.58
KMIALLSHR 65,309.16
294.37M 		0.72%
464.00
BKTi 45,925.86
14.05M 		0.45%
203.62
OGTi 33,858.81
2.02M 		0.58%
194.60
Symbol Bid/Ask High/Low
Name Last High/Low Chg/%Chg
BITCOIN FUTURES 77,060.00 77,430.00
76,450.00 		220.00
0.29%
BRENT CRUDE 105.86 107.24
104.27 		1.09
1.04%
RICHARDS BAY COAL MONTHLY 129.00 129.00
129.00 		0.75
0.58%
ROTTERDAM COAL MONTHLY 142.50 0.00
0.00 		0.35
0.25%
USD RBD PALM OLEIN 1,182.50 1,182.50
1,182.50 		0.00
0.00%
CRUDE OIL - WTI 97.43 98.69
96.12 		0.97
1.01%
SUGAR #11 WORLD 18.46 19.06
18.39 		-0.60
-3.15%
Latest News
November 03, 2026 at 04:18 PM GMT+05:00

SECP cracks down on Ponzi, Pyramid investment schemes

November 03, 2026 at 04:15 PM GMT+05:00

Gold price in Pakistan remain unchanged

November 03, 2026 at 04:07 PM GMT+05:00

PKR holds largely flat against USD

November 03, 2026 at 04:01 PM GMT+05:00

PSX Closing Bell: The Green Giant Awakens

Pakistan Stock Movers
Name Last Chg/%Chg
Name Last Chg/%Chg